Article
[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
Annales de pathologie - 1 Jan 2016
Hamard Cécile, Ruppert Anne-Marie, Lavole Armelle, Rozensztajn Nathalie, Antoine Martine, Cadranel Jacques, Wislez Marie
Abstract excerpt
Recently, developments of therapies that target abnormally activated signaling pathways are increasing for patients with non-small cell lung cancer. EGFR mutations are found in about 10% of lung cancers, especially in adenocarcinoma, women and non-smokers. Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC....
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials as Topic
- Female
- Genes, Neoplasm
- Humans
- Lung Neoplasms
- Male
- Molecular Targeted Therapy
- Mutation
- Neoplasm Proteins
- Protein Kinase Inhibitors
- Signal Transduction